Viatris: Mylan No Longer Subject of Antitrust Investigation by Justice Dept
By Chris Wack
Viatris said the Antitrust Division of the U.S. Department of Justice has advised that it no longer considers Mylan, and its former president, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry.
In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.
The Civil Division of the DOJ has also informed the company that it doesn't expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
Viatras said this outcome affirms its position that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees.
The company said it will continue to defend itself against the remaining civil lawsuits pertaining to these matters.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 02, 2024 08:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations